TrialNature communications2025

Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial.

Nan Niu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.